Correction Notice: Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use

Since the publication of the article entitled “Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use” (HemaSphere. 2023;7(8):e907), the authors have requested a correction. Author Michael von Bergwelt should instead be listed as Michael von Bergwelt-Baildon. This has now been adjusted.

The changes have been made online: https://journals.lww.com/hemasphere/fulltext/2023/08000/inferior_outcomes_of_eu_versus_us_patients_treated.2.aspx